TITLE PAGE

Title:

Elastin degradation markers are elevated in never-smokers with past history of prolonged exposure to secondhand tobacco smoke and are inversely associated with their lung function

Short Title: Elastin degradation with secondhand smoke exposure

Authors:

Jelena Mustra Rakic, PhD^{*,1,2}, Siyang Zeng, MS^{*,3,4}, Linnea Rohdin-Bibby⁵, Erin L Van Blarigan, ScD⁶, Xingjian Liu, PhD⁷, Shuren Ma, PhD⁷, John P Kane, MD, PhD², Rita Redberg, MD, MS^{5,8}, Gerard M. Turino, MD⁷, Eveline Oestreicher Stock, MD^{#,2,5,8}, Mehrdad Arjomandi, MD^{#,1,3,9,10}

* These authors contributed equally to this work.

Co-senior authors.

¹ Center for Tobacco Control Research and Education, University of California, San Francisco, California, USA

² Cardiovascular Research Institute, University of California, San Francisco, California, USA

³ Medical Service, San Francisco Veterans Affairs Medical Center; San Francisco; California, USA

⁴ Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA

⁵Flight Attendant Medical Research Institute (FAMRI) Bland Lane Center of Excellence on Secondhand Smoke, University of California, San Francisco, California, USA

⁶Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA

⁷Department of Medicine, Mt Sinai-St Luke's-Roosevelt Hospital, New York, New York, USA

⁸Division of Cardiology, University of California, San Francisco, California, USA

⁹Division of Pulmonary, Critical Care, Allergy and Immunology, and Sleep Medicine, University of California, San Francisco, California, USA

¹⁰Division of Occupational and Environmental Medicine; University of California, San Francisco, California, USA

Emails:

JMR: Jelena.MustraRakic@ucsf.edu

SZ: siyang.zeng@ucsf.edu

LR: Linnea.Rohdin-Bibby@ucsf.edu

ELVB: erin.vanblarigan@ucsf.edu

XL: XingjianLiu@gmail.com

SM: shurenma@yahoo.com

JPK: John.Kane@ucsf.edu

RR: Rita.Redberg@ucsf.edu

GMT: gmt1@columbia.edu

EOS: Eveline.Stock@ucsf.edu

MA: Mehrdad.arjomandi@ucsf.edu

§Corresponding author:

Mehrdad Arjomandi, MD

Department of Medicine

University of California, San Francisco

San Francisco Veterans Affairs Medical Center

Building 203, Room 3A-128, Mailstop 111-D

4150 Clement Street, San Francisco, CA 94121

TEL (415) 221-4810 x24393

EMAIL mehrdad.arjomandi@ucsf.edu

Authors' Contributions

Designed the current manuscript study: JMR, SZ, RR, GMT, EOS, MA

Developed study protocols: XL, SM, RR, GMT, EOS, MA

Collected samples: LR, RR, EOS, MA

Analyzed samples: XL, SM, GMT

Collected, analyzed, and interpreted data: JMR, SZ, LR, ELVB, MA

Prepared the manuscript: JMR, SZ, MA

Edited the manuscript: JMR, SZ, ELVB, LR, XL, SM, JK, RR, GMT, EOS, MA

Obtained funding: JMR, SZ, RR, GMT, EOS, MA

Summary conflict of interest:

Authors report no conflict of interest related to this work

Funding:

This work was supported by:

1. Flight Attendant Medical Research Institute (FAMRI) (012500WG and CIA190001 to MA; CIA150034 to GMT; FAMRI Center of Excellence Award#012500 to RR).
2. California Tobacco-Related Disease Research Program (TRDRP) (T29IR0715 to MA).
3. The Department of Veterans Affairs (CXV-00125 to MA).
4. National Library of Medicine Training Grant (NIH: T15LM007442 to SZ)
5. Postdoctoral Training in Tobacco Control Research (NIH/NCI: T32 CA113710 to JMR)

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The statements and conclusions in this publication are those of the authors and not necessarily those of the funding agency. The mention of commercial products, their source, or their use in connection with the material reported herein is not to be construed as an actual or implied endorsement of such products.

Keywords: biomarkers, desmosine/isodesmosine, flight attendants, lung damage, secondhand smoke exposure

ABBREVIATIONS:

Cellulose fiber powders (CF)

Chronic obstructive pulmonary disease (COPD)

Desmosine/isodesmosine (D/I)

Diffusing capacity (DCO)

Flight attendants (FAs)

Flight attendant medical research institute (FAMRI)

Forced expiratory flow (FEF)

Forced expiratory volume in 1 second (FEV₁)

Forced vital capacity (FVC)

Secondhand smoke (SHS)

Solid phase extraction (SPE)

ABSTRACT

Background- Prolonged past exposure to secondhand tobacco smoke (SHS) in never-smokers is associated with occult obstructive lung disease and abnormal lung function, in particular reduced diffusing capacity. Previous studies have shown ongoing SHS exposure to be associated with increased elastin degradation markers (EDM) desmosine and isodesmosine.

Research Question- Are EDM levels elevated in persons with remote history of SHS exposure, and are those levels associated with reduced lung function?

Study Design and Methods- We measured the plasma levels of EDM from 193 never-smoking flight attendants with history of remote but prolonged SHS exposure in aircraft cabin and 103 nonsmoking flight attendants or sea-level control participants without history of cabin SHS exposure, and examined those levels versus their lung function with adjustment for covariates. The cabin SHS exposure was estimated based on airline employment history and dates of smoking ban enactment. EDM plasma levels were quantified by high-performance liquid chromatography and tandem mass spectrometry.

Results- The median [interquartile range; IQR] plasma EDM level for all participants was 0.30 [0.24 to 0.36] ng/mL with a total range of 0.16 to 0.65 ng/mL. Plasma EDM levels were elevated in those with history of exposure to cabin SHS compared to those not exposed (0.33 ± 0.08 vs. 0.26 ± 0.06 ng/mL; age- and sex-adjusted $P < 0.001$). In those with history of cabin SHS-exposure, higher EDM levels were associated with lower diffusing capacity (parameter estimate (PE) [95%CI]=4.2 [0.4 to 8.0] %predicted decrease per 0.1 ng/mL increase in EDM; $P=0.030$). Furthermore, EDM levels were inversely associated with FEV₁, FEV₁/FVC, and FEF₂₅₋₇₅ (PE [95%CI]=5.8 [2.1 to 9.4], 4.0 [2.2 to 5.7], and 12.5 [5.8 to 19.2] % predicted decrease per 0.1 ng/mL increase in EDM, respectively) ($P < 0.001$).

Interpretation- Prolonged past exposure to SHS, even when remote, is associated with higher systemic elastin degradation markers that in turn is associated with lower lung function and in particular reduced diffusing capacity.

BACKGROUND

Secondhand tobacco smoke (SHS), a heterogeneous mixture of the sidestream smoke from the burning end of the cigarette and the smoke exhaled by the smoker, is four to 12 times more toxic than the mainstream smoke inhaled by the smoker.^{1, 2} Over the past several decades, a large body of scientific evidence has implicated long-term exposure to SHS as a risk factor for pulmonary diseases including chronic obstructive lung disease (COPD) in both smokers and never-smokers.³⁻⁶ Remarkably, even remote exposure to secondhand tobacco smoke (SHS) has been shown to be associated with respiratory symptoms and lung function abnormalities consistent with obstructive lung disease.^{3, 7-11}

Desmosine and isodesmosine (D/I) are two cross-linked pyridinoline amino acids specific to peptides that are generated from degradation of elastin, a key extracellular protein that provides resilience and elasticity to tissues and is primarily located in lungs, aorta, and skin.¹² Lung elastin is a recognized target for injury in COPD, and systemic levels of D/I, which are specific for elastin degradation, are elevated in COPD as well as in those without COPD but with acute exposure to tobacco smoke, direct or secondhand.¹³⁻¹⁵ However, it is unclear whether past remote exposure to SHS in those without a diagnosis of COPD is also associated with continued lung injury, elastin degradation, and elevated levels of D/I.

In this study, we aimed to investigate the relationship between remote prolonged exposure to SHS and molecular markers of elastin degradation (plasma D/I) in never-smokers without a diagnosis of COPD, and how those levels are associated with lung function as a way to speculate about the source of elastin degradation product. We hypothesized that there is a positive association between past SHS exposure and plasma D/I, and that the level of plasma D/I is inversely associated with lung function. Presence of such associations would then suggest that past exposure to SHS could result in ongoing lung injury and elastin degradation, contributing to obstructive lung disease.

STUDY DESIGN AND METHODS

Study design

To examine our hypothesis above, we took advantage of a “natural experiment” and examined the plasma levels of D/I and lung function from a cohort of healthy flight attendants with no known history of lung diseases including no known COPD who worked for the United States airlines beginning before the smoking ban enactment. These flight attendants were exposed to relatively heavy cabin occupational SHS during their employment for many years and for long periods of time each day.¹⁶ This set up allowed for a robust objective quantification of cabin SHS exposure using employment history and the dates on which different airlines implemented the smoking bans on domestic and international flights.¹⁶ Flight attendants who began working after the smoking ban enactment were also recruited as an “unexposed” reference group. Furthermore, blood samples and lung function data from baseline visit of previous participants in MOSES (Multicenter Ozone Study of oldEr Subjects; ClinicalTrials.gov ID# NCT01487005) were also used as additional “unexposed” non-flight attendant reference group.¹⁷

Study population

The between June 2014 and October 2019, 241 flight attendants were enrolled as part of an ongoing clinical investigation of the health effects of exposure to cabin SHS in the Flight Attendant Medical Research Institute (FAMRI) Center of Excellence at the University of California San Francisco (UCSF). Thirty-two of those flight attendants had smoked more than 100 cigarettes in their lifetime and were thus excluded from the study. From the 209 remaining participants, 193 had begun their airline employment before the smoking ban enactment and had worked in smoky cabin and were considered “exposed” and 16 were “unexposed”.

All participants gave written informed consent, and the study was approved by the UCSF Institutional Review Board (IRB). Flight attendants were excluded from the study if they smoked more than 100 cigarettes in their lifetime.

The MOSES cohort has been described previously.¹⁷ Briefly, between 2012 and 2015, 87 healthy nonsmoker adults between the ages of 55 to 70 years old were recruited to participate in a clinical trial investigating the cardiopulmonary health effects of exposure to ambient levels of ozone in a controlled exposure experiments at three centers across the United States. The study consisted of an initial screening visit to determine the eligibility of participants during which blood samples and lung function measurements were collected and incorporated in a biorepository. The data and blood samples from MOSES participants were used in this study to provide a reference “unexposed” group.

All MOSES participants gave written informed consent approved by the respective centers IRB (the University of Rochester Medical Center (URMC), University of North Carolina (UNC), and University of California San Francisco (UCSF)).

Measurement of cabin SHS exposure

SHS exposure was characterized by a questionnaire developed by UCSF Flight Attendant Medical Research Institute (FAMRI) Center of Excellence,¹⁸ and modified to acquire information on airline-related occupational history, as described previously.^{10, 16} Briefly, this included employer airlines, duration of employment, and flight routes with quantification of “cabin SHS exposure” as the number of years during which the crewmembers were exposed to SHS in aircraft. Other possible sources of SHS exposure were also explored by questioning participants about their non-cabin exposures in additional settings, as described previously.¹⁹ Consideration for cabin section was not made.

Plasma collection and measurements of plasma D/I levels

A non-fasting blood draw at the time of the visit was obtained via forearm venipuncture. The blood samples were collected on ice and centrifuged at 4°C and 1,200 x g for 10 minutes. Plasma was transferred in a new tube and stored at -80°C for further analyses.

Measurement of D/I was done as previously described.²⁰ Briefly, plasma samples were acid-hydrolyzed in concentrated hydrochloric acid at 100°C-110°C for 24 hours, and were then applied to a cellulose fiber powders (CF1 or CF11) cartridge to purify. A synthetic desmosine-d4 served as the internal standard for processing plasma samples and measuring D/I. High-performance liquid chromatography and tandem mass spectrometry methods were used for measuring D/I levels.

Pulmonary function testing

Full pulmonary function testing (PFT) was done for 82 of the eligible participating 209 flight attendants. The remaining 127 participating flight attendants underwent spirometry without plethysmography or diffusing capacity (DCO) measurement.

Full PFT (N=82) were performed in the seated position using a model Vmax 229 CareFusion (CareFusion Corp., Yorba Linda, CA) and nSpire body plethysmograph (nSpire Health Inc., Longmont, CO). This included measurement of the flow-volume curve and spirometry;²¹ lung volume by single breath dilution;^{22, 23} and plethysmography;²⁴ airway resistance during panting at functional residual capacity (FRC);^{25, 26} and single breath carbon monoxide diffusing capacity.²⁷ Spirometry without plethysmography or diffusing capacity measurement for the 127 flight attendants was done using a portable spirometer (EasyOne, NDD Medical Technologies) in the seated position. MOSES lung function testing procedures have been described previously.¹⁷ Briefly, spirometry was performed in seated position using a dry rolling seal spirometer calibrated weekly: UPMC used a KoKo PFT

Spirometer (Nspirehealth, Longmont, CO); UNC used VIASYS 10.2-L model 1022 (SensorMedics; Palm Springs, CA); and UCSF employed an S&M Instrument, PDS Instrumentation (Louisville, CA).

All pulmonary function studies were conducted according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines.²⁸⁻³³ Participants did not undergo bronchodilator administration. The Global Lung Initiative (GLI) predicted formulas were used to compute the percent predicted values as well as lower and upper limit of normal values for spirometry measures (FEV₁/FVC, FEV₁, FVC, FEF₂₅₋₇₅).³⁴ Crapo predicted formulas were used to compute the percent predicted values as well as lower and upper limits of normal values for diffusing capacity.^{35, 36} Spirometric COPD was defined using Global Initiative for Obstructive Lung Disease (GOLD) criteria unless otherwise specified.³⁷

Statistical analysis

Participants' characteristics including demographics, years of SHS exposure, and lung function measures were examined and summarized within all participants and with respect to subgroups with or without cabin SHS exposure. The adjusted plasma D/I levels were computed by calculating the residual values of the raw plasma D/I levels and their predicted values from a linear regression model of the plasma D/I levels over age, sex, height, and weight. A comparison of the distributions was performed using an unpaired t-test for each continuous variable or a Chi-squared test for each binary or categorical variable. The P values and the descriptive statistics including the mean $\pm$ standard deviation (SD), median [1st quartile, 3rd quantile] for continuous variables or N (%) for binary and categorical variables were presented.

The associations between plasma D/I levels and lung function measures were examined, in the whole group of participants and the subgroup of those who had cabin SHS exposure, using linear

regression modelling with adjustment for covariates including age, sex, height, and weight. The associations between having history of cabin SHS exposure as well as years of cabin SHS exposure and lung function measures were examined using linear regression modelling with adjustment for the same covariates. For each individual model using one of the lung volume measures as the dependent variable, the total number of participants involved in the model and the parameter estimate with a 95% confidence interval and a P value for plasma D/I levels or years of SHS exposure were reported accordingly.

The associations between plasma D/I levels and years of SHS exposure were examined using linear regression modelling with adjustments for the same covariates in the subgroup of those who had cabin SHS exposure. The difference in plasma D/I levels between the subgroups with and without cabin SHS exposure was assessed using linear regression modeling with adjustments for the same covariates in the whole group of participants. For these models using plasma D/I levels as the dependent variable, the total number of participants involved in the model and the parameter estimate with a 95% confidence interval and a P-value for years of SHS exposure or the binary indicator of having past SHS exposure were reported accordingly.

Statistical analyses were conducted using the R (version 3.6) statistical software. A significance level of $\alpha < 0.05$ was used to determine statistical significance.

RESULTS

Participants' characteristics

From the total of 241 flight attendants who were initially recruited into the study, 32 were excluded because of they were not never-smokers. Among the remaining 209, 193 (92.3%) had been exposed to cabin SHS and 16 had not been exposed to cabin SHS. Additionally, 87 non-flight attendants healthy nonsmoking participants (from MOSES) were included in the SHS unexposed group. Overall, 296 participants were included in the analyses (**Figure 1**) consisting of 193 (65.2%) exposed to cabin SHS and 103 (34.8%) unexposed.

Participants' characteristics are shown in **Table 1**. The average age of participants (N=296) was 64.0 ± 7.8 years. The SHS unexposed group were younger (59.3 ± 6.0 years) than the SHS exposed group (66.5 ± 7.4 years) with majority being women in both groups (63% and 81%, respectively). The cohort was primarily composed of people of White racial background (85.5%), but also included people who identified their racial background as Asian, African American, Indian and Alaskan Native, Native Hawaiian or other Pacific Islander. There was no significant race/ethnicity difference between SHS exposed and unexposed groups. The average body mass index (BMI) was 24.4 ± 3.5 Kg/m² (21 participants were obese defined by BMI >30 Kg/m²), with no significant difference in BMI between SHS exposed and unexposed groups. Amongst all participants, the total years of airline employment and cabin SHS exposure were 31.1 ± 11.4 and 17.8 ± 9.4 years, respectively.

Lung function measurements

Pulmonary function test measurements are shown in **Table 2**. Although none of the participants had clinical diagnosis of COPD, 53 (17.9%) and 22 (7.4%) had abnormal FEV₁ to FVC ratio consistent with spirometric COPD by Global Initiative for Obstructive Lung Disease (GOLD) (FEV₁/FVC <0.70) and

the lower limit of normal (LLN) criteria, respectively ($FEV_1/FVC=0.74\pm0.07$ at $94\pm9\%$ predicted). Among the SHS exposed group, 41 (21.2%) and 14 (7.3%) participants had abnormal FEV_1/FVC consistent with spirometric COPD by GOLD and LLN criteria, respectively. Among the SHS unexposed group, 12 (11.7%) participants had $FEV_1/FVC < 0.70$, but only 8 (7.8%) had spirometric COPD by LLN criteria. The FEV_1 was within the normal range for both unexposed and exposed participants as a whole, but was reduced at 1.91 ± 0.55 L ($79\pm20\%$ predicted) in the SHS exposed participants with spirometric COPD.

The diffusion capacity, which was measured only in 82 participants (all flight attendants), was (20.5 ± 4.2 mL/min/mmHg at $80\pm12\%$ predicted), and was below the LLN in 32 (39%) of participants. Although not statistically significant, the diffusion capacity of the SHS exposed group was lower than that of the SHS unexposed group (20.2 ± 4.1 versus 23.1 ± 3.8 mL/min/mmHg [80 ± 12 versus $84\pm12\%$ predicted]). Similarly, the diffusing capacity of SHS exposed group with spirometric COPD was non-significantly lower than that of the SHS exposed group without spirometric COPD (18.6 ± 2.9 versus 20.5 ± 4.2 mL/min/mmHg [75 ± 10 versus $81\pm12\%$ predicted]).

Associations of plasma levels of elastin degradation products with lung function measures

In linear regression models adjusted for age, sex, height and weight, plasma levels of elastin degradation products (desmosine and isodesmosine [D/I]) were inversely associated with FEV_1 , FVC, FEV_1/FVC , FEF_{25-75} , and DCO among all participants (FEV_1 : $\beta=-1.76$ L, $P<0.001$; FVC: $\beta=-1.43$ L, $P=0.002$; FEV_1/FVC : $\beta=-26\%$, $P<0.001$; FEF_{25-75} : $\beta=-2.74$ L, $P<0.001$; and DCO: $\beta=-9.98$ mL/min/mmHg, $P=0.037$) (**Table 3**). Similar associations were found with the percent predicted values (**Figure 2**).

Among the subgroup with cabin SHS-exposure, we found similar inverse association between plasma levels of D/I and FEV₁, FEV₁/FVC, FEF₂₅₋₇₅, and DCO in adjusted models (FEV₁: β =-1.47L, P=0.001; FEV₁/FVC: β =-31%, P<0.001; FEF₂₅₋₇₅: β =-2.55L, P<0.001; and DCO: β =-10.92 mL/min/mm Hg, P=0.025; respectively) (**Table S1**). Similar associations were found with the percent predicted values (**Figure 2**). When SHS-exposed group was divided into the subgroups with and without COPD, similar directions of the associations were observed, although they did not reach statistical significance (**Table S1**).

Associations of SHS exposure with plasma levels of elastin degradation products

Among all participants, the unadjusted and adjusted (age, sex, height, and weight-adjusted) plasma levels of D/I were significantly elevated in the SHS-exposed group compared to the SHS-unexposed group (unadjusted levels: 0.33±0.08 vs. 0.26±0.06 ng/mL, P<0.001 (**Table 2**); adjusted levels in **Figure 3**). Among SHS-exposed group, those with spirometric COPD had significantly elevated levels of plasma D/I compared to those without spirometric COPD (unadjusted levels: 0.38±0.08 vs. 0.32±0.08 ng/mL, P<0.001 (**Table 2**); adjusted levels in (**Figure 3**).

In the univariate model, plasma levels of D/I were directly associated with years of SHS exposure, and with age, but not with length of employment as flight attendants (P<0.001, P<0.001, and P=0.43, respectively) (**Table S2**). However, in the multivariate model, after adjusting for age, sex, height, and weight; years of cabin SHS exposure and total years of flight employment were not associated with plasma D/I levels (**Table S2**).

Associations of SHS exposure with lung function measures

Among all participants, history of exposure to cabin SHS was inversely associated with FEV₁, FVC, and FEF₂₅₋₇₅ in models adjusted for age, sex, height, and weight (FEV₁: $\beta=-0.25L$, $P<0.001$; FVC: $\beta=-0.30L$, $P<0.001$; and FEF₂₅₋₇₅: $\beta=-0.23L$, $P=0.020$) (**Table 4**). As an example, those exposed to cabin SHS smoke had an FEV₁ that was 247 mL lower compared to those who were not exposed to cabin SHS. The associations between exposure to SHS and FEV₁/FVC or DCO were in the hypothesized directions but did not reach statistical significance.

DISCUSSION

In this study, we found that never-smoking flight attendants who had a remote history of occupational exposure to SHS had significantly higher systemic (plasma) levels of elastin degradation markers, desmosine and isodesmosine (D/I), compared to nonsmoking individuals with no such history of occupational SHS exposure. Furthermore, we found that among those never-smoking SHS-exposed flight attendants, those with spirometric COPD had higher systemic levels of D/I compared to those without spirometric COPD. While the source of the higher systemic elastin degradation markers in those exposed to cabin SHS (and also those with spirometric COPD) that we observed in this study is unknown, the inverse association of plasma D/I with lung function does suggest that pulmonary elastin degradation at least in part contributes to this process. This is remarkable because it implies that even 25 years after the occupational exposure to cabin SHS (smoking was banned on all domestic and international flights after 1995), there is ongoing differential elastin damage in these never-smokers who were exposed to SHS in the cabin. While there have been previous reports about increased systemic levels of D/I in the setting of acute exposure to SHS,¹³ to our knowledge, this is the first report of describing evidence of lung damage with such remote exposure to SHS.

Many studies have reported D/I levels to be an indicator of lung damage associated with decreased lung function.^{14, 38-42} First, studies that supported the association between destruction of lung elastin with occurrence of airspace enlargement characteristic for emphysema and increased urinary D/I were done in animal models.^{39, 40, 42} Later, human studies confirmed similar findings.^{15, 41, 42} Stone et al extensively explored levels of D/I in relation to presence of COPD, or with smoking status.⁴³ They found higher excretion of D/I in urine of COPD patients, and in smokers without presence of COPD compared to healthy lifetime nonsmokers, suggesting smoking and the presence of COPD to be independently associated with elevated urinary D/I levels. Other studies have reported increased D/I levels in smokers

and COPD patients, even before clinical symptoms of COPD occurs.¹⁴ Slowik et al demonstrated that not only smokers, but also non-smokers exposed to SHS, have higher levels of D/I compared to a control without SHS exposure.¹³ Although, prior studies reported increased plasma D/I due to SHS exposure, our study is the first to document a long-term effect from remote past SHS exposure on systemic levels of D/I, an association between measures of lung function including lung function indices suggestive of small airways and distal lung damage with plasma levels of D/I and past SHS exposure.

Our finding that cabin SHS exposure from many years ago is associated with current elevation of systemic levels of elastin degradation products is quite remarkable but its biological plausibility is supported by the available literature. Excessive and persistent inflammation is a driving force in lung injury and development of COPD, and several studies have shown that airway inflammation persists long after cessation of smoke exposure, including SHS.⁴⁴⁻⁴⁹ These findings suggest exposure to smoke could initiate self-perpetuating processes that prevent resolution of the inflammatory response, which in turn cause persistent injury and damage to the lung evident from the elevated levels of elastin degradation products many years after, despite removal of the original insult.

Although no longer being exposed to the high intensity SHS that they experienced in aircraft cabins, flight attendants experience increased rates of respiratory illnesses, compared to the general population.^{7-9,3,7} McNelly et al⁹ reported roughly three-fold increase in chronic bronchitis prevalence among flight attendants, when compared to age matched general U.S. population in the National Health and Nutrition Examination Survey (NHANES), despite the flight attendants having lower prevalence of smoking. Furthermore, the odds of being diagnosed with chronic bronchitis increased with tenure of flight attendants.⁹ In addition, Beatty et al found increased prevalence of chronic bronchitis, emphysema/COPD, and sinus problems among FAs compared to the U.S. general population.⁷ Arjomandi et al reported never-smoking flight attendants who were exposed to past cabin SHS to have

decreased diffusing capacity, with more than half of them having diffusing capacity below the lower limit of the 95% prediction interval for their age, sex and height.^{10, 16} Further, they also had decreased maximal airflow at mid- and low-lung volumes together with pulmonary function evidence of air trapping suggesting airflow obstruction.³

LIMITATIONS

Our study has several limitations. First, exposure to cabin SHS was estimated based on self-reported data regarding airline employment years. Yet, airline employment history could provide a relatively accurate measure of cabin SHS exposure. Moreover, any error in the flight attendants' recall of employment history is not expected to be related to plasma D/I or lung measurements. Second, while we observed significant association between history of cabin SHS exposure and higher plasma D/I levels in the univariate linear regression modeling, in the multivariate modeling, years of cabin SHS exposure association with plasma D/I levels did not reach statistical significance after adjusting for age, sex, height, and weight. This could be due to the relationship between D/I levels and years of SHS exposure not being linear; it is possible there is a threshold effect of SHS. Indeed, this is consistent with previous studies reporting the association between diffusing capacity and SHS exposure among those FA who were exposed to SHS for more than 10 years.¹⁰ Nevertheless, in the current study, in the categorical comparisons of exposed and unexposed participants, plasma D/I levels were significantly higher in those exposed to SHS as a group compared to the unexposed after adjusting for covariates (age, sex, height, and weight). Third, beyond the history of cabin SHS exposure in the past, flight attendants face other environmental exposures, such as low atmospheric pressure and radiation exposure, which could contribute to lung damage measured by D/I levels. However, we observed

significant association only between years of cabin SHS exposure and plasma D/I, and did not observe significant association between total years of airline employment and D/I levels.

INTERPRETATION

Collectively, our study documents the long-term adverse effects of exposure to SHS on pulmonary structure and function. It provides evidence that past exposure to SHS, even when remote, is associated with higher systemic elastin degradation markers, which in turn is indicative of continued lung damage and declining lung function despite the cessation of culprit exposure. Our study furthermore implicates plasma D/I as a sensitive biomarker of lung damage in at risk population regardless of whether their risk of disease is due to current or past exposure to direct or secondhand tobacco smoke.

TAKE-HOME POINTS

Study Question: Whether EDM levels are elevated in persons with history of SHS exposure in the past, and whether those levels are associated with reduced lung function.

Results: Levels of EDM are elevated in persons with SHS exposure in the past; increase in EDM levels is associated with reduced lung function.

Interpretation: Plasma D/I may prove to be a sensitive biomarker of lung abnormalities in population that was heavily exposed to SHS in the past.

REFERENCES

1. Schick S, Glantz S. Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke. *Tob Control*. Dec 2005;14(6):396-404.
2. Schick SF, Glantz SA. Sidestream cigarette smoke toxicity increases with aging and exposure duration. *Tobacco control*. 2006;15(6):424-429.
3. Arjomandi M, Haight T, Redberg R, Gold WM. Pulmonary function abnormalities in never-smoking flight attendants exposed to secondhand tobacco smoke in the aircraft cabin. *Journal of occupational and environmental medicine*. 2009;51(6):639-646.
4. Fischer F, Kraemer A. Meta-analysis of the association between second-hand smoke exposure and ischaemic heart diseases, COPD and stroke. *BMC public health*. 2015;15:1202-1202.
5. Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. *Lancet*. Jan 8 2011;377(9760):139-146.
6. van Koeveerden I, Blanc PD, Bowler RP, Arjomandi M. Secondhand Tobacco Smoke and COPD Risk in Smokers: A COPD Gene Study Cohort Subgroup Analysis. *Copd*. Apr 2015;12(2):182-189.
7. Beatty AL, Haight TJ, Redberg RF. Associations between respiratory illnesses and secondhand smoke exposure in flight attendants: A cross-sectional analysis of the Flight Attendant Medical Research Institute Survey. *Environmental health : a global access science source*. 2011;10(1):81-81.
8. Ebbert JO, Croghan IT, Schroeder DR, Murawski J, Hurt RD. Association between respiratory tract diseases and secondhand smoke exposure among never smoking flight attendants: a cross-sectional survey. *Environ Health*. Sep 26 2007;6:28.
9. McNeely E, Gale S, Tager I, et al. The self-reported health of U.S. flight attendants compared to the general population. *Environ Health*. Mar 10 2014;13(1):13.
10. Arjomandi M, Haight T, Sadeghi N, Redberg R, Gold WM. Reduced exercise tolerance and pulmonary capillary recruitment with remote secondhand smoke exposure. *PLoS One*. 2012;7(4):e34393.
11. Arjomandi M, Zeng S, Geerts J, et al. Lung volumes identify an at-risk group in persons with prolonged secondhand tobacco smoke exposure but without overt airflow obstruction. *BMJ Open Respir Res*. 2018;5(1):e000284.
12. Mithieux SM, Weiss AS. Elastin. *Adv Protein Chem*. 2005;70:437-461.
13. Slowik N, Ma S, He J, et al. The effect of secondhand smoke exposure on markers of elastin degradation. *Chest*. Oct 2011;140(4):946-953.
14. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. *Eur Respir J*. Nov 2008;32(5):1146-1157.
15. Turino GM. Chronic Obstructive Pulmonary Disease. A Biomarker and a Potential Therapy. *Ann Am Thorac Soc*. Feb 2018;15(Suppl 1):S15-S17.
16. Arjomandi M, Haight T, Redberg R, Gold WM. Pulmonary function abnormalities in never-smoking flight attendants exposed to secondhand tobacco smoke in the aircraft cabin. *J Occup Environ Med*. Jun 2009;51(6):639-646.
17. Arjomandi M, Balmes JR, Frampton MW, et al. Respiratory Responses to Ozone Exposure. MOSES (The Multicenter Ozone Study in Older Subjects). *Am J Respir Crit Care Med*. May 15 2018;197(10):1319-1327.

18. Eisner MD, Wang Y, Haight TJ, Balmes J, Hammond SK, Tager IB. Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. *Ann Epidemiol.* May 2007;17(5):364-373.
19. Koeverden I, Blanc PD, Bowler RP, Arjomandi M. Secondhand Tobacco Smoke and COPD Risk in Smokers: A COPD Gene Study Cohort Subgroup Analysis. *COPD.* Apr 2015;12(2):182-189.
20. Ma S, Lin YY, Cantor JO, et al. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. *Chronic Obstr Pulm Dis.* Nov 18 2016;4(1):34-44.
21. Comroe Jr. JH. Pulmonary Function Tests. *Methods in Medical Research.* Chicago, Illinois: Year Book Publishers, Inc.; 1950:188.
22. Mitchell MM, Renzetti AD, Jr. Evaluation of a single-breath method of measuring total lung capacity. *Am Rev Respir Dis.* Apr 1968;97(4):571-580.
23. Burns CB, Scheinhorn DJ. Evaluation of single-breath helium dilution total lung capacity in obstructive lung disease. *Am Rev Respir Dis.* Oct 1984;130(4):580-583.
24. Dubois AB, Botelho SY, Bedell GN, Marshall R, Comroe JH, Jr. A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. *J Clin Invest.* Mar 1956;35(3):322-326.
25. Dubois AB, Botelho SY, Comroe JH, Jr. A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. *J Clin Invest.* Mar 1956;35(3):327-335.
26. Briscoe WA, Dubois AB. The relationship between airway resistance, airway conductance and lung volume in subjects of different age and body size. *J Clin Invest.* Sep 1958;37(9):1279-1285.
27. Blakemore WS, Forster RE, Morton JW, Ogilvie CM. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. *J Clin Invest.* Jan 1957;36(1 Part 1):1-17.
28. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med.* Sep 1995;152(3):1107-1136.
29. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J.* Oct 2005;26(4):720-735.
30. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. *Eur Respir J.* Jul 2005;26(1):153-161.
31. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J.* Aug 2005;26(2):319-338.
32. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J.* Nov 2005;26(5):948-968.
33. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. *Eur Respir J.* Sep 2005;26(3):511-522.
34. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J.* Dec 2012;40(6):1324-1343.
35. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis.* Jun 1981;123(6):659-664.

36. Crapo RO, Morris AH, Gardner RM. Reference values for pulmonary tissue volume, membrane diffusing capacity, and pulmonary capillary blood volume. *Bull Eur Physiopathol Respir*. Nov-Dec 1982;18(6):893-899.
37. Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. Jan 1 2021;203(1):24-36.
38. Lindberg CA, Engström G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. *European Respiratory Journal*. 2012;39(4):839.
39. Goldstein RA, Starcher BC. Urinary excretion of elastin peptides containing desmosin after intratracheal injection of elastase in hamsters. *J Clin Invest*. May 1978;61(5):1286-1290.
40. Janoff A, Chanana AD, Joel DD, et al. Evaluation of the urinary desmosine radioimmunoassay as a monitor of lung injury after endobronchial elastase instillation in sheep. *Am Rev Respir Dis*. Sep 1983;128(3):545-551.
41. Harel S, Janoff A, Yu SY, Hurewitz A, Bergofsky EH. Desmosine radioimmunoassay for measuring elastin degradation in vivo. *Am Rev Respir Dis*. Nov 1980;122(5):769-773.
42. Stone PJ, Bryan-Rhadfi J, Lucey EC, et al. Measurement of urinary desmosine by isotope dilution and high performance liquid chromatography. Correlation between elastase-induced air-space enlargement in the hamster and elevation of urinary desmosine. *Am Rev Respir Dis*. Aug 1991;144(2):284-290.
43. Stone PJ, Gottlieb DJ, O'Connor GT, et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. Apr 1995;151(4):952-959.
44. King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. *Clinical and translational medicine*. 2015;4(1):68-68.
45. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*. Jun 24 2004;350(26):2645-2653.
46. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. *N Engl J Med*. Jun 4 2009;360(23):2445-2454.
47. Panagiotakos DB, Pitsavos C, Chrysoshoou C, et al. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. *Am J Med*. Feb 1 2004;116(3):145-150.
48. Flouris AD, Metsios GS, Carrillo AE, et al. Acute and short-term effects of secondhand smoke on lung function and cytokine production. *Am J Respir Crit Care Med*. Jun 1 2009;179(11):1029-1033.
49. Bhat TA, Kalathil SG, Bogner PN, et al. Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. *J Immunol*. Apr 15 2018;200(8):2927-2940.

FIGURE LEGENDS

Figure 1- Participants' flowchart. The flow of participants through the study screening and procedures.

Figure 2- Association of Systemic levels of elastin degradation products (plasma desmosine and isodesmosine [D/I]) with lung function. Scatter plots representing the association of adjusted plasma levels of elastin degradation products (D/I) with lung function among cabin SHS-exposed participants. P-values ($P_{adj. \beta}$) were obtained from multivariate regression models with adjustment for age, sex, height, and weight. Blue and red dots represent SHS-unexposed and SHS-exposed participants, respectively.

Figure 3- Systemic levels of elastin degradation products (plasma desmosine and isodesmosine) in SHS-exposed and unexposed participants (with and without spirometric COPD). Plasma levels of elastin degradation products (D/I) from exposed and unexposed participants without and with adjustments are plotted using violin plots (**A** and **B**, respectively). Plasma levels of D/I from exposed and unexposed participants without and with COPD are plotted using violin plots (**C**). Adjusted plasma levels of D/I were obtained by computing the residuals from regression modeling with adjustment for age, sex, height, and weight. P-values were obtained from both pairwise t-test comparisons (**P**) and multivariate regression models with adjustment for age, sex, height, and weight ($P_{adj. \beta}$).

TABLES

Table 1- Participant characteristics

	All participants (N=296)	Unexposed (N=103)	Exposed (N=193)	P-value*	Exposed w/o COPD (N=152)	Exposed w COPD (N=41)	P- value#
Age (years)							
Mean±SD	64.0±7.8	59.3±6.0	66.5±7.4	<0.001	65.7±7.67	69.4±5.67	0.003
Median [Q1, Q3]	64.0 [58.0, 70.0]	59.0 [56.0, 63.5]	68.0 [61.0, 71.0]		67.0 [60.0, 71.0]	71.0 [66.0, 73.0]	
Sex (Female)	221 (74.7%)	65 (63.1%)	156 (80.8%)	0.003	125 (82.2%)	31 (75.6%)	0.633
Height (cm)							
Mean±SD	167±8	169±9	166±7	0.014	166±8	166±6	0.983
Median [Q1, Q3]	166 [162, 173]	170 [164, 175]	165 [161, 170]		165 [160, 170]	165 [163, 170]	
Weight (kg)							
Mean±SD	68.5±12.2	71.0±12.7	67.1±11.8	0.035	67.1±11.8	66.8±11.8	0.991
Median [Q1, Q3]	67.1 [59.0, 76.7]	69.2 [61.4, 80.1]	65.8 [58.1, 74.8]		65.5 [58.1, 74.9]	66.2 [57.7, 72.1]	
BMI (kg/m²)							
Mean±SD	24.4±3.5	24.7±3.4	24.2±3.6	0.545	24.3±3.6	24.1±3.6	0.959
Median [Q1, Q3]	24.0 [21.6, 26.8]	24.0 [22.4, 26.7]	23.9 [21.4, 26.8]		23.7 [21.4, 27.1]	24.3 [21.3, 26.2]	
Race							
Indian or Alaskan native	2 (0.7%)	1 (1.0%)	1 (0.5%)	0.903	1 (0.7%)	0 (0%)	0.873
Asian	16 (5.4%)	4 (3.9%)	12 (6.2%)	0.699	10 (6.6%)	2 (4.9%)	0.923
Black or African American	8 (2.7%)	6 (5.8%)	2 (1.0%)	0.053	1 (0.7%)	1 (2.4%)	0.607
Native Hawaiian or other Pacific Islander	1 (0.3%)	1 (1.0%)	0 (0%)	0.391	0 (0%)	0 (0%)	NA
White	253 (85.5%)	87 (84.5%)	166 (86.0%)	0.938	130 (85.5%)	36 (87.8%)	0.933
Other or unknown	16 (5.4%)	4 (3.9%)	12 (6.2%)	0.699	9 (5.9%)	3 (7.3%)	0.947
Hispanic	8 (2.7%)	6 (5.8%)	2 (1.0%)	0.054	2 (1.3%)	0 (0%)	0.761
Flight history (years)							
Mean±SD	31.1±11.4	22.9±10.3	31.5±11.3	0.042	31.3±10.9	32.4±12.8	0.637
Median [Q1, Q3]	33.0 [24.0, 40.0]	24.0 [18.0, 27.5]	33.0 [26.0, 40.0]		33.0 [25.8, 39.3]	35.0 [27.0, 42.0]	
Cabin SHS exposure (years)							
Mean±SD	17.8±9.4	0±0	17.8±9.4	NA	17.5±9.41	19.0±9.20	0.354

Median [Q1, Q3]	17.5 [10.0, 26.0]	0 [0, 0]	17.5 [10.0, 26.0]		17.8 [10.0, 25.0]	17.0 [12.0, 28.0]	
-----------------	-------------------	----------	-------------------	--	-------------------	-------------------	--

Footnote: Values are mean $\pm$ standard deviation (SD) and Median [Q1, 1st quartile; Q3, 3rd quartile]. * P-values (unpaired t-test) for comparison between cabin SHS exposed and unexposed participants. # P-values (unpaired t-test) for comparison between SHS exposed participants with and without COPD. Abbreviation: SHS, secondhand smoke; BMI, body mass index; COPD, chronic obstructive pulmonary disease.

Table 2- Pulmonary function test and elastin degradation product measurements.

	All participants (N=296)	Unexposed (N=103)	Exposed (N=193)	P-value*	Exposed w/o COPD (N=152)	Exposed w COPD (N=41)	P-value#
FEV₁ (L)							
Mean±SD	2.55±0.68	2.93±0.62	2.36±0.62	<0.001	2.48±0.589	1.91±0.548	<0.001
Median [Q1, Q3]	2.43 [2.10, 2.93]	2.79 [2.50, 3.35]	2.24 [1.97, 2.60]		2.36 [2.11, 2.77]	1.92 [1.72, 2.16]	
FEV₁ (% predicted)							
Mean±SD	97±18	101±14.0	95±20	0.004	99.1±17.3	78.9±19.5	<0.001
Median [Q1, Q3]	98 [86, 107]	101 [91, 110]	95 [84, 106]		97.8 [87.4, 107]	77.7 [69.9, 90.6]	
FVC (L)							
Mean±SD	3.44±0.85	3.89±0.84	3.20±0.76	<0.001	3.26±0.770	3.00±0.677	0.116
Median [Q1, Q3]	3.25 [2.84, 3.90]	3.77 [3.17, 4.52]	3.05 [2.72, 3.49]		3.08 [2.75, 3.56]	2.98 [2.54, 3.27]	
FVC (% predicted)							
Mean±SD	102±16	105±14	100±17	0.023	102±17.0	95.8±16.9	0.157
Median [Q1, Q3]	101 [91.3, 112]	104 [96.3, 115]	99.0 [89.8, 111]		100 [90.0, 111]	95.2 [81.6, 110]	
FEV₁/FVC							
Mean±SD	0.74±0.07	0.76±0.05	0.73±0.08	0.012	0.76±0.03	0.63±0.09	<0.001
Median [Q1, Q3]	0.75 [0.71, 0.78]	0.75 [0.72, 0.79]	0.74 [0.70, 0.78]		0.76 [0.73, 0.79]	0.66 [0.61, 0.68]	
FEV₁/FVC < 0.70	53 (17.9%)	12 (11.7%)	41 (21.2%)	0.140	0 (0%)	41 (100%)	NA
FEV₁/FVC (% predicted)							
Mean±SD	94±9	96±6	94±10	0.064	97.0±4.96	80.9±11.6	<0.001
Median [Q1, Q3]	95.0 [90.3, 99.4]	95.4 [92.5, 99.9]	94.7 [89.6, 99.3]		97.1 [93.2, 100]	84.9 [78.8, 87.5]	
Peak expiratory flow (L/s)							
Mean±SD	368±118	395±85.0	366±120	0.668	386±122	310±94.6	0.001
Median [Q1, Q3]	343 [300, 409]	390 [343, 450]	342 [297, 406]		355 [311, 419]	309 [259, 333]	
FEF₂₅₋₇₅ (L/s)							
Mean±SD	2.05±0.84	2.43±0.77	1.85±0.81	<0.001	2.10±0.713	0.958±0.390	<0.001
Median [Q1, Q3]	1.97 [1.45, 2.58]	2.31 [1.84, 2.97]	1.78 [1.30, 2.32]		1.98 [1.58, 2.56]	0.960 [0.670, 1.26]	
FEF₂₅₋₇₅ (% predicted)							
Mean±SD	890±32	95±27	87±35	0.061	97.1±30.0	47.7±19.2	<0.001
Median [Q1, Q3]	88.3 [68.7, 110]	92.3 [75.7, 110]	83.8 [64.6, 105]		93.8 [73.0, 113]	48.4 [34.1, 63.7]	
DCO (mL/min/mmHg)							
Mean±SD	20.5±4.2	23.1±3.8	20.2±4.1	0.14	20.5±4.23	18.6±2.88	0.172
Median [Q1, Q3]	20.2 [17.4, 22.9]	23.2 [20.8, 25.6]	19.9 [17.3, 22.2]		20.2 [17.4, 22.5]	18.6 [17.3, 19.7]	

DCO (% predicted)							
Mean±SD	80±12	84±12	80±12	0.576	80.5±11.8	74.9±9.70	0.254
Median [Q1, Q3]	80 [71, 89]	84 [75, 92]	79 [71, 88]		81.1 [71.9, 89.8]	75.0 [68.1, 80.2]	
D/I (ng/mL)							
Mean±SD	0.31±0.08	0.26±0.06	0.33±0.08	<0.001	0.319±0.0775	0.378±0.0832	<0.001
Median [Q1, Q3]	0.30 [0.24, 0.36]	0.24 [0.22, 0.29]	0.33 [0.27, 0.37]		0.310 [0.264, 0.358]	0.367 [0.340, 0.414]	
Adjusted D/I (normalized score)							
Mean±SD	0±0.07	-0.02±0.06	0.01±0.07	0.002	0.002±0.07	0.04±0.07	0.020
Median [Q1, Q3]	-0.01 [-0.05, 0.04]	-0.02 [-0.06, 0.01]	0.001 [-0.04, 0.05]		-0.003 [-0.04, 0.04]	0.02 [-0.01, 0.09]	

Footnote: Values are mean ± standard deviation (SD) and Median [Q1, 1st quartile; Q3, 3rd quartile]. * P-values (unpaired t-test) for comparison between cabin SHS exposed and unexposed participants. # P-values (unpaired t-test) for comparison between SHS exposed participants with and without COPD. Abbreviation: SHS, secondhand smoke; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF, forced expiratory flow; FET, forced expiratory time; DCO, diffusing capacity; D/I, desmosine/isodesmosine.

Table 3- Associations between plasma levels of elastin degradation products (desmosine and isodesmosine, D/I) and lung function measures.

Dependent variable	N	All participants PE $\pm$ SEM (95% CI)	P-value
Airway indices			
FEV ₁ (L)	288	-1.76 $\pm$ 0.38 (-2.51 to -1.01)	<0.001
FEV ₁ (% predicted)	288	-65.84 $\pm$ 14.59 (-94.56 to -37.12)	<0.001
FVC (L)	288	-1.43 $\pm$ 0.46 (-2.34 to -0.52)	0.002
FVC (% predicted)	288	-40.38 $\pm$ 13.6 (-67.14 to -13.62)	0.003
FEV ₁ /FVC	288	-0.26 $\pm$ 0.05(-0.36 to -0.15)	<0.001
FEV ₁ /FVC (% predicted)	288	-33.56 $\pm$ 6.76 (-46.87 to -20.25)	<0.001
Small airways indices			
FEF ₂₅₋₇₅ (L/s)	287	-2.74 $\pm$ 0.61 (-3.94 to -1.54)	<0.001
FEF ₂₅₋₇₅ (% predicted)	286	-125.52 $\pm$ 27.04 (-178.75 to -72.28)	<0.001
Distal (parenchymal) lung indices			
DCO (mL/min/mm Hg)	82	-9.98 $\pm$ 4.71 (-19.37 to -0.59)	0.037
DCO (% predicted)	82	-38.26 $\pm$ 18.34 (-74.79 to -1.73)	0.040

Footnote: Models were adjusted for age, sex, height, and weight. Abbreviation: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF, forced expiratory flow; DCO, diffusing capacity; PE, parameter estimate; SEM, standard error of mean; CI, confidence interval.

Table 4- Associations between cabin SHS exposure and lung function measures.

Dependent variables	All participants Independent variable: Exposed (Y/N)			All participants Independent variable: Years of exposure		
	N	PE±SEM (95% CI)	P-value	N	PE±SEM (95% CI)	P-value
Airway indices						
FEV ₁ (L)	288	-0.247±0.061 (-0.368 to -0.126)	<0.001	288	-0.004±0.003 (-0.010 to 0.0014)	0.140
FEV ₁ (% predicted)	288	-8.923±2.349 (-13.547 to -4.298)	<0.001	288	-0.14±0.11 (-0.37 to 0.08)	0.198
FVC (L)	288	-0.303±0.073 (-0.446 to -0.160)	<0.001	288	-0.006±0.004 (-0.013 to 0.001)	0.108
FVC (% predicted)	288	-8.200±2.146 (-12.424 to -3.976)	<0.001	288	-0.13±0.10 (-0.33 to 0.07)	0.198
FEV ₁ /FVC (%)	288	-0.01±0.01 (-0.03 to 0.01)	0.311	288	0.0001±0.0004 (-0.0009 to 0.0007)	0.798
FEV ₁ /FVC (% predicted)	288	-1.30±1.12 (-3.51 to 0.90)	0.246	288	-0.02±0.05 (-0.12 to 0.09)	0.766
Small airways indices						
FEF ₂₅₋₇₅ (L/s)	287	-0.230±0.099 (-0.424 to -0.036)	0.020	287	-0.005±0.005 (-0.015 to 0.004)	0.268
FEF ₂₅₋₇₅ (% predicted)	286	-10.052±4.388 (-18.690 to -1.414)	0.022	286	-0.27±0.21 (-0.68 to 0.15)	0.205
Distal (parenchymal) lung indices						
DCO (mL/min/mm Hg)	82	-1.206±1.185 (-3.566 to 1.153)	0.311	82	-0.004±0.037 (-0.079 to 0.070)	0.906
DCO (% predicted)	82	-4.949±4.602 (-14.114 to 4.217)	0.285	82	-0.02±0.14 (-0.30 to 0.27)	0.913

Footnote: Models were adjusted for age, sex, height, and weight. Abbreviation: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF, forced expiratory flow; DCO, diffusing capacity; PE, parameter estimate; SEM, standard error of mean; CI, confidence interval.

Figure 1- Participants' flowchart. The flow of participants through the study screening and procedures.

Figure 2- Association of Systemic levels of elastin degradation products (plasma desmosine and isodesmosine [D/I]) with lung function. Scatter plots representing the association of adjusted plasma levels of elastin degradation products (D/I) with lung function among cabin SHS-exposed participants. P-values ($P_{adj. \beta}$) were obtained from multivariate regression models with adjustment for age, sex, height, and weight. Blue and red dots represent SHS-unexposed and SHS-exposed participants, respectively.

Figure 3- Systemic levels of elastin degradation products (plasma desmosine and isodesmosine) in SHS-exposed and unexposed participants (with and without spirometric COPD). Plasma levels of elastin degradation products (D/I) from exposed and unexposed participants without and with adjustments are plotted using violin plots (**A** and **B**, respectively). Plasma levels of D/I from exposed and unexposed participants without and with COPD are plotted using violin plots (**C**). Adjusted plasma levels of D/I were obtained by computing the residuals from regression modeling with adjustment for age, sex, height, and weight. P-values were obtained from both pairwise t-test comparisons (P) and multivariate regression models with adjustment for age, sex, height, and weight ($P_{adj. \beta}$).